Physician profile
Deepak Dhawan
NPI 1184727182
$2,082.18
in general payments reported to CMS, 2019-2025
32 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $158 · 2021: $323 · 2022: $436 · 2023: $365 · 2024: $580 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148 · Education: $16.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.02 |
| Education | $16.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $213.51 | 2023-2024 | |
| Novo Nordisk INC | $195.12 | 2020-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $161.65 | 2020-2025 | Keytruda |
| Ethicon INC. | $158.57 | 2022 | |
| Amgen INC. | $139.91 | 2021-2024 | Evenity, Prolia |
| Abbvie INC. | $127.82 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.87 | 2021-2024 | Ninlaro |
| Glaxosmithkline, LLC. | $103.61 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $83.40 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.59 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $65.40 | 2021-2025 | Calquence, Lokelma |
| Dexcom, INC. | $60.45 | 2022-2023 | Dexcom G6 Transmitter |
| Organogenesis INC. | $48.11 | 2022 | |
| Astellas Pharma US INC | $46.40 | 2020 | |
| Pfizer INC. | $42.85 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $40.11 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $38.08 | 2023 | Gemtesa |
| Kyowa Kirin, INC. | $37.79 | 2024 | Crysvita |
| Blueprint Medicines Corporation | $33.88 | 2023 | Ayvakit |
| Linus Health, INC. | $31.43 | 2024 | Core Cognitive Evaluation |
| Boston Scientific Corporation | $31.35 | 2020 | |
| Spectrum Pharmaceuticals INC. | $26.60 | 2025 | Rolvedon |
| Recordati_rare_diseases_inc. | $23.34 | 2025 | Enjaymo |
| Taiho Oncology, INC. | $23.30 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $22.13 | 2023 | Imbruvica |
| Azurity Pharmaceuticals, INC. | $20.84 | 2024 | Vivimusta |
| Acrotech Biopharma INC. | $20.52 | 2021 | |
| Beigene USA, INC. | $20.37 | 2024 | Brukinsa |
| Incyte Corporation | $20.36 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.23 | 2024 | |
| Cardinal Health 414 LLC | $20.13 | 2024 | Kit For The Preparation of Lymphoseek (Technetium Tc 99m Tilmanocept) |
| Heron Therapeutics, INC. | $18.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Dhawan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.